The United States Congress is reviving a bipartisan health care agreement at the end of 2024 that includes reforms to pharmacy benefit managers (PBMs), the mid-tier firms that negotiate drug prices.[2][3] This agreement does not include the extension of preferential tax credits for ACA (Obamacare) premium payments.[2][5] The package includes reforms to PBM business practices, hospital billing transparency measures, funding for public programs, expanding telemedicine flexibilities in Medicare, and drug patent reforms.[2] Senate Finance Committee leaders Mike Crapo (Republican) and Ron Wyden (Democrat) are leading the negotiations, with the goal of finalizing an agreement by January 30 on HHS funding.[3][5] The deal was initially canceled after criticism from Elon Musk and then-President-elect Trump.[2][3] The push for PBM reforms continues amid allegations of anti-competitive practices that hurt independent pharmacies and keep drug prices high.[3] In 2023, the Senate unanimously approved the PBM reform by a ratio of 26-0.[5] The White House supports this effort.[3]